Frank Davis , MBA

Dr. Christoffer Clemmensen talks about the effectiveness of GLP-1 drugs for weight loss and how they compare to each other. Learn about the first-generation drug, Saxenda, and the more potent semaglutide. Find out the percentage of people who experience significant weight loss with these drugs. Clip from this podcast conversation: https://lnkd.in/gUQiug_G #Obesity #Metabolism #Diet #Health #WeightManagement #Biology #Science #Ozempic #GLP1 #Hormones #Nutrition

4

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

6

#1 rule of new technology in medicine for the US = What’s the payment model? = Most traditional and reliable payment model is still fee for service codes. It appears we’ll get new codes from the American Medical Association that could mean more #RemotePatientMonitoring reimbursement by 2025 - If the American Medical Association approves new changes and Medicare and private payers follow suit, providers that expand their remote patient monitoring programs to fit the new codes will gain the most benefits for their patients and clinics https://lnkd.in/eCcCnG8S #DigitalHealth #TransformingCare

12

2 Comments

Dr. Mary Claire Haver MD, Founder of The Galveston Diet @drmaryclaire Sneak Peak of the Interview with Dr. Mary Claire Haver! What motivated you to write “The New Menopause” Book and what key messages or insights do you hope readers take away from it? "As I began speaking with more and more women as a result of the work I’d done on The Galveston Diet, I found that more and more, women were hungry for information about what they were experiencing. They were visiting their doctors only to be told there were no solutions for them, or that it is just part of aging. The lack of information available to women left them feeling helpless and hopeless. I just really wanted to write a comprehensive, science-backed book that would arm women with the facts about menopause, their symptoms, and their options for treatment." How does your book "The New Menopause," recently released in 2024, empower women to ensure lasting health and well-being throughout their lives, establishing itself as the go-to guide for midlife wellness in both current and future generations? "I aim in this book to provide the latest research and information around symptoms, organ systems, and the many ways that women can seek to treat their symptoms to ensure that they don’t have to suffer but can, in fact, thrive in the latter portion of their lives. Each woman is unique and it’s so important that she understands what is going on with her own body so that she can advocate for herself. I aim to provide a full toolkit for consideration in the treatment of symptoms. The toolkit includes quality nutrition, beneficial sleep, movement, stress reduction, possible pharmacology, and community." Photo courtesy of Dr. Mary Claire Haver Subscribe at www.modwomen.co to read the full feature in our upcoming magazine! #theagelesssociety #agelesssociety40plus #queens #life #women #womensupportingwomen #womenempowerment #ageless #fyp #modwomen #modwomenlife #modwomenmovement #modwomensociety #modwomenmagazine #menopause #perimenopause #postmenopause #womenshealth #womenshealthmatters #thenewmenopause #medical #doctor #interview

1

Great piece by Juliana "Julie" Reed in @Stat outlining the missed savings for the US healthcare system including employers and patients that have been caused by #PBMs greed in choosing higher priced drugs because all of the price concessions and profits they make are based on the list price of the drug. It never was a physician’s choice to choose a biosimilar as the PBMs control that. Now the big 3 ins cos/PBMs are mandating “fail first”biosimilars that physicians can’t afford to buy based on the cost of the drug and underwater reimbursement. We will never realize the true potential of biosimilar savings until the perverse incentive to choose medications that make the most money for these publicly traded PBMs is taken out of formulary construction.

15

1 Comment

As we continue #NationalSmallBusinessWeek led by the U.S. Small Business Administration, we celebrate Conquest Research, an innovative provider of clinical trial services focused on neurology, orthopedics and general medicine. . Learn more about Conquest at https://lnkd.in/eaEbgsA8 or contact the Conquest Deal Team: Scott Snow and Ken Clark #smallbusinessweek #sba #smallbusinessowners #smallbusinesses #thepartnerforfounders #founders #partnership

25

Today, episode #6 in WP x American College of Sports Medicine series dropped! This is the sixth episode of our special podcast series exploring the Sept/Oct themed issue of the American College of Sports Medicine’s Health & Fitness Journal on professionalization and advocacy. In this episode, we’ll discuss the importance of advocacy, with Mike Goscinski, the author for the article in the themed issue entitled "Empowering Health and Fitness: Advocating for Industry Representation and Policy Influence." Get insights into the legislative landscape affecting fitness businesses as Mike outlines the Health and Fitness Association's efforts to monitor and amend state laws, ensuring they are fair yet consumer-friendly. From click-to-cancel requirements to auto-renewal policies, understand the nuances and challenges of broad legislation that impacts gym memberships. Mike shares concrete examples, illustrating the practical implications of these advocacy efforts. Hear how direct engagement with lawmakers led to the successful amendment of around 50 bills this year, safeguarding both business interests and consumer rights. Finally, we tackle the critical need to reshape the health and fitness industry's image through targeted advocacy and lobbying. Mike discusses strategies to counter outdated stereotypes and emphasize the sector's vital role in public health, especially post-pandemic. Learn about the economic impact of the industry and the importance of grassroots advocacy, engaging with trade associations, and building connections with local policymakers. With practical action items for exercise professionals, this episode is a must-listen for anyone committed to advancing the professionalization of the fitness industry. Don't miss out on these valuable insights—hit play now! Listen at the link in the comments below! #fitness #fitpros #health #healthcare #wellness #fitnesspodcast #fitnessindustry

6

1 Comment

From ages 40 to 74 years, #mammography is now recommended every other year for women at average risk of #breastcancer. #USPSTF #breastcancerscreening Full report at https://lnkd.in/eZETdbR6

2

Walgreens and Boehringer Ingelheim announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and research. Through this collaboration, Boehringer Ingelheim will leverage select Walgreens community pharmacies as clinical trial sites for people living with obesity, overweight and type 2 diabetes. The effort aims to dismantle barriers, improve access, and address equitable health representation in clinical trials, especially among Black and Hispanic adults who are more likely to have obesity in the U.S. and have historically been underrepresented. "Embracing our pharmacy clinical trial centers in this study underscores our joint commitment to community health and innovation," said Ramita Tandon, Chief Clinical Trials Officer at Walgreens. "This model not only provides foundational education on clinical research for patients but also empowers individuals, offering them a new pathway to engage in their healthcare through clinical trial participation. It's a step forward in transforming the landscape of clinical research, helping to make clinical trials more inclusive and accessible." Additionally, Boehringer is partnering with EmVenio Research to complement this initiative by introducing mobile research units to extend reach and provide additional options for participation. "Boehringer is proud to embrace this community-centric approach to clinical research with Walgreens and EmVenio," said Lennart Jungersten, Senior Vice President, Medicine & Regulatory Affairs at Boehringer Ingelheim U.S. "By bringing clinical trials into the heart of local communities, we're making them more accessible, helping to provide access to diverse populations with pressing health needs to participate in our clinical trials. Boehringer Ingelheim is committed to helping those living with overweight and obesity to transform lives for generations to come." "At EmVenio, we believe that innovation is meaningful and access to clinical trial research should be universal. Our partnership with Boehringer Ingelheim exemplifies our commitment to breaking down barriers and expanding access to transformative healthcare solutions," says Thad Wolfram, President, EmVenio Research. "By bringing clinical trials directly to local communities, we're not just conducting research, we're fostering inclusivity and diversity in clinical trials."  #diversity #inclusivity #clinicaltrials #EmVenio  #Walgreens #BoehringerIngelheim #LifeForward 👉 https://lnkd.in/ddr443Gd

603

4 Comments

Has Regeneron been successful with EYLEA HD® (aflibercept) Injection HCP as the patent for regular Eylea expires in June 2027? There will be 5 biosimilars, including 2 labeled as interchangeable, available next year. Regeneron reported their earnings yesterday and below 👇 you see their quarterly sales of both regular Eylea and HD. Sales of Eylea HD grew 30% Q over Q from $304M to $392M ($40M of Q3 is due to increased distributor inventories). But is that enough? The problem is over $1.1 B or 2/3 of Eylea sales remain in regular Eylea. With loss of its patent, Eylea will lose its pricing power, its moat, entirely. It will become one of 6 equivalent commodities. Basic economics dictates that without a moat, competition will drive prices to marginal costs and the profits to zero. The stock market seems to agree with my analysis as $REGN stock is down 10% overnight and 30% in 2 months. In the end, patients will be the winners. #retina #ophthalmology #optometry

10

1 Comment

#Anemia is growing faster globally than we ever thought. You've probably noticed the increase in social media posts promoting Patient Blood Management #pbm conferences, surgical products, iron supplements, and medical advancements in this critical health area. Please support these posts. These companies form the foundation of potential cures for anemia worldwide. Consider this: The smallest amount of air blown into a balloon will automatically increase its size and visibility. Our Anemia Awareness initiative is like that balloon. We’ve already grown significantly thanks to their efforts. Now, imagine the future. These companies are doing everything they can individually to capture public attention. Sadly, their combined volume may never be enough to cross the waters and reach the public’s ears. A simple bridge could allow easy access for both healthcare providers and the public. We believe that access reaches far more people than sheer volume. Our mission is to build a stronger public-to-healthcare provider engagement infrastructure, facilitating the transfer of innovation and providing greater access to education. This is a new concept for anemia, and we anticipate new partnerships and ideas that will expedite awareness even further. Until then, we deeply appreciate all collective efforts—together, we will defeat public enemy number one: Anemia. Fresenius Kabi Terumo Blood and Cell Technologies BCT Haemonetics CSL Vifor Medtronic Baxter International Inc. Ethicon, Inc. Masimo Instrumentarium LivaNova Octapharma ProCell Surgical Inc. Immucor, Inc. Abbott PharmaNutra Wrig Nanosystems Werfen Sanguina, Inc., Inc Cerus Dignity Health Blood Management Brazil Por Dra. Roseny Rodrigues Society for the Advancement of Patient Blood Management, Inc. (SABM)

9

Did you know that lifetime risk of ALS is 1 in 400? For most people with ALS, there are currently no treatments to significantly slow or stop disease progression? Learn more about this devastating disease and how you can make a difference. www.als.net/May #EndALS #ALSawarenessMonth

8

Do you wonder if your peers in the industry have the same worries, struggles and fears that you do when it comes to #patientaccess? It can be hard to be that vulnerable! We have some good news! MMIT (Managed Markets Insight & Technology) just talked to over 300 of your peers - pharma execs - to learn what’s keeping them up at night—and what gets them going in the morning. Check out the findings and our expert analysis in MMIT’s first-annual State of Patient Access research report. Have questions? Want to talk about it? Let us know! https://lnkd.in/eW7JHTAE

8

The FDA has recently approved two transformative therapies, offering life-changing medicine to 100,000 individuals in the U.S. affected by sickle cell disease. Our leaders, Philip Cyr, SVP, and Erin Lopata, VP, Director - Access Experience Team, collaborated with Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, to share their insights with CGTLive on the innovative CMS CGT Access Model. This model is set to revolutionize patient access, enhance health outcomes, and manage healthcare costs more effectively. Dive deeper into the model and its impact: https://lnkd.in/ee6U-pmN #HealthcareInnovation #SickleCellDisease #PatientCare #FDAApproval #cellandgenetherapy

36

1 Comment